MedPath

Pipeline Analysis Reveals 20+ Drug Candidates for c-MET+ NSCLC Treatment

• DelveInsight's latest pipeline report identifies over 20 pharmaceutical companies actively developing treatments for c-MET-positive Non-Small Cell Lung Cancer, with multiple promising candidates in various clinical stages.

• AbbVie's telisotuzumab vedotin enters Phase 3 trials in January 2025, comparing its efficacy against docetaxel in previously treated c-Met overexpressing NSCLC patients.

• Key players including AbbVie, Janssen, and Beijing Pearl Biotechnology are advancing novel therapeutic approaches, from bispecific antibodies to targeted small molecules for c-MET NSCLC treatment.

A comprehensive pipeline analysis has revealed a robust development landscape for c-MET-positive Non-Small Cell Lung Cancer (NSCLC) treatments, with more than 20 pharmaceutical companies actively advancing therapeutic candidates through various stages of development.
AbbVie is leading a significant Phase 3 clinical trial starting January 2025, evaluating telisotuzumab vedotin (ABBV-399) against docetaxel in previously treated patients. This open-label, randomized, controlled global study specifically targets individuals with c-Met overexpressing, EGFR wildtype, locally advanced or metastatic non-squamous NSCLC.

Novel Therapeutic Approaches

Among the promising candidates, Janssen Research & Development's JNJ-61186372 stands out as an innovative EGFR-MET bispecific antibody. Developed using Genmab's DuoBody technology platform, this antibody targets both activating and resistant EGFR and MET mutations and amplifications. The drug shows particular promise for patients with Exon 20 mutation insertions, who typically show limited response to existing EGFR-targeted therapies and immune checkpoint inhibitors.
Beijing Pearl Biotechnology is advancing PLB1001, an oral c-Met inhibitor designed to disrupt cancer cell survival pathways. The drug works by selectively binding to c-Met, inhibiting phosphorylation and signal transduction pathways in tumor cells that overexpress the c-Met protein.

Diverse Treatment Modalities

The pipeline encompasses various therapeutic approaches, including:
  • Small molecules
  • Bispecific antibodies
  • Immunotherapies
  • Monoclonal antibodies
  • Gene therapies
These treatments are being developed for different routes of administration, ranging from oral and intramuscular to intravenous and intratumoral delivery methods.

Key Pipeline Candidates

Several other promising therapies are in development, including:
  • Glumetinib
  • Tepotinib
  • INC280 (Novartis)
  • APL-101 Oral Capsules
  • MCLA-129
  • Osimertinib

Development Landscape

The current pipeline features drugs across multiple development stages, from discovery and preclinical to Phase III trials. This diverse development landscape suggests a strong potential for new treatment options for c-MET+ NSCLC patients in the coming years.
Industry leaders including AbbVie, Janssen Research & Development, Beijing Pearl Biotechnology, and Novartis are investing significant resources in developing these targeted therapies, reflecting the growing importance of precision medicine in oncology treatment strategies.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Non-Small Cell Lung Cancer Clinical Trial Pipeline Sees Significant Growth

The Non-Small Cell Lung Cancer (NSCLC) clinical trial pipeline is experiencing a boom with over 100 companies actively developing more than 120 therapies. Advances in targeted therapies, focusing on genetic mutations like EGFR, ALK, ROS1, BRAF, and MET, are improving treatment outcomes. Recent FDA designations and clinical trial initiations highlight the ongoing innovation and potential for new treatments in the NSCLC domain.

AbbVie's Telisotuzumab Vedotin Shows Promise in c-Met Overexpressing NSCLC

AbbVie's telisotuzumab vedotin (Teliso-V) demonstrated a 35% overall response rate in patients with high c-Met expression in the LUMINOSITY trial.
The FDA granted breakthrough therapy designation to Teliso-V, highlighting its potential to significantly improve outcomes in NSCLC patients.

Telisotuzumab Adizutecan Shows Promise in c-Met-Expressing Solid Tumors

Telisotuzumab adizutecan (ABBV-400) demonstrates antitumor activity in non-small cell lung cancer (NSCLC) and gastroesophageal cancer (GEA) patients in a Phase 1 study.
In EGFR wild-type NSCLC, ABBV-400 achieved a 43.8% objective response rate (ORR) and an 85.4% clinical benefit rate at 2.4/3.0 mg/kg every three weeks.

NCFB Pipeline Shows Promise with Over 15 Companies Developing New Therapies

The non-cystic fibrosis bronchiectasis (NCFB) market is experiencing growth due to rising prevalence and increased awareness, leading to early diagnosis and treatment.
Over 15 companies are actively developing more than 15 NCFB drugs, aiming to improve the treatment landscape for this chronic lung condition.

Advancements in NSCLC Treatment: Amivantamab, Perioperative Immunotherapy, and HER2-Targeted ADCs

Amivantamab plus chemotherapy was approved for EGFR exon 19 deletions or exon 21 L858R substitution mutations in advanced NSCLC after progression on EGFR TKIs.
Perioperative durvalumab and nivolumab have been approved for resectable NSCLC, expanding treatment options for patients without EGFR or ALK alterations.

Melanoma Treatment Landscape Evolves with Novel Immunotherapies and Targeted Approaches

The FDA granted fast-track approval to Amtagvi, a Tumor-Infiltrating Lymphocyte (TIL) therapy, for metastatic melanoma patients who have failed other treatments, marking a significant advancement in cellular immunotherapy.
Neoadjuvant immunotherapy has become the standard of care for stage III melanoma patients with resectable tumors, as highlighted at the European Society for Medical Oncology (ESMO) Congress.

Mantle Cell Lymphoma Pipeline Shows Promise with Novel Targeted Therapies

The Mantle Cell Lymphoma (MCL) pipeline is robust, featuring over 20 companies developing more than 22 therapies.
Key players like AbbVie and BeiGene are advancing novel drugs, including BTK inhibitors and Bcl-2 inhibitors, to improve MCL treatment.

Perioperative Nivolumab and Neoadjuvant Immunotherapy Show Promise in Resectable NSCLC

Perioperative nivolumab significantly extends event-free survival (EFS) in resectable NSCLC, with a median EFS increase from 17.0 to 40.1 months.
Neoadjuvant nivolumab, alone or with ipilimumab, demonstrates durable long-term survival benefits, particularly in patients achieving major pathological response (MPR) or pathological complete response (PCR).

Advancements in HER2-Mutant NSCLC Therapies: A Pipeline Overview

Several companies are actively developing novel therapies for HER2-mutant non-small cell lung cancer (NSCLC), indicating a robust pipeline.
Key players like AstraZeneca and Dizal Pharmaceuticals are advancing treatments such as Trastuzumab deruxtecan and DZD-9008 through clinical trials.

Study on Telisotuzumab Vedotin Shows Promise for c-Met-Positive NSCLC Patients

A first-in-human study of Telisotuzumab Vedotin (Teliso-V), an antibody-drug conjugate, has shown promising results for patients with c-Met-positive non-small-cell lung cancer (NSCLC), with a recommended phase II dose established based on safety and tolerability.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy